RGRX fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
RGRX has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company